Mosanna Therapeutics is developing MOS-118, a first-in-class pharmacologic upper airway dilator muscle activator for the treatment of obstructive sleep apnea (OSA). MOS-118 is an intranasally delivered pan-K+ channel inhibitor that acts locally on the pressure sensing nerves located in the nasopharynx. It’s intranasal route of administration and mechanism of action result in minimal systemic exposure, offering a patient-friendly, safe and effective treatment for those unable or unwilling to tolerate CPAP.
Go to website: https://mosanna.com/